You are here

Article Text

Article menu

Download PDFPDF

XML
Original research
β-adrenergic blockade is associated with a reduced risk of 90-day mortality after surgery for hip fractures
  1. Ahmad Mohammad Ismail1,2,
  2. Tomas Borg1,2,
  3. Gabriel Sjolin2,3,
  4. Arvid Pourlotfi2,3,
  5. Sebastian Holm1,
  6. Yang Cao4,
  7. Per Wretenberg1,2,
  8. Rebecka Ahl2,5,6,
  9. Shahin Mohseni7
  1. 1Department of Orthopedic Surgery, Örebro University Hospital, Örebro, Sweden
  2. 2School of Medical Sciences, Örebro University, Örebro, Sweden
  3. 3Department of Surgery, Örebro University Hospital, Örebro, Sweden
  4. 4Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden
  5. 5Division of Trauma and Emergency Surgery, Department of Surgery, Karolinska University Hospital, Stockholm, Sweden
  6. 6Division of Surgery, CLINTEC, Karolinska Institutet, Stockholm, Sweden
  7. 7Division of Trauma and Emergency Surgery, Department of Surgery, Örebro University Hospital, Örebro, Sweden
  1. Correspondence to Dr Shahin Mohseni; mohsenishahin{at}yahoo.com

Abstract

Background There is a significant postoperative mortality risk in patients subjected to surgery for hip fractures. Adrenergic hyperactivity induced by trauma and subsequent surgery is thought to be an important contributor. By downregulating the effect of circulating catecholamines the increased risk of postoperative mortality may be reduced. The aim of the current study is to assess the association between regular β-blocker therapy and postoperative mortality.

Methods This cohort study used the prospectively collected Swedish National Quality Registry for hip fractures to identify all patients over 40 years of age subjected to surgery for hip fractures between 2013 and 2017 in Örebro County, Sweden. Patients with ongoing β-blocker therapy at the time of surgery were allocated to the β-blocker-positive cohort. The primary outcome of interest was 90-day postoperative mortality. Risk factors for 90-day mortality were evaluated using Poisson regression analysis.

Results A total of 2443 patients were included in this cohort of whom 900 (36.8%) had ongoing β-blocker therapy before surgery. The β-blocker positive group was significantly older, less fit for surgery based on their American Society of Anesthesiologists classification and had a higher prevalence of comorbidities. A significant risk reduction in 90-day mortality was detected in patients receiving β-blockers (adjusted incidence rate ratio=0.82, 95% CI 0.68 to 0.98, p=0.03).

Conclusions β-blocker therapy is associated with a significant reduction in 90-day postoperative mortality after hip fracture surgery. Further investigation into this finding is warranted.

Level of evidence Therapeutic study, level III; prognostic study, level II.

  • femoral fractures
  • hip fractures
  • emergency treatment
  • mortality
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/tsaco-2020-000533

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Background

    Hip fractures predominantly affect the elderly. With an ageing global population an increase in the incidence of such events is expected.1 The majority of hip fractures are treated surgically, as opposed to conservatively, and are associated with high postoperative mortality. The risk of early postoperative mortality ranges from 10% to 16%,2 and is as high as 27% in the first postsurgical year.2–4 Despite new improved innovations in orthopedic surgery and multidisciplinary team approaches to decision-making, postoperative mortality numbers after surgery for hip fractures have remained unchanged during the last decade.2 5

    There is high level of scientific evidence that β-adrenergic blockade in cardiac surgery is associated with better overall outcomes.6 Recent studies have detected a significant association between β-adrenergic blockage and an increase in survival in patients suffering from severe traumatic injuries,7–9 and those subjected to major intra-abdominal surgery.10 11 It is a held hypothesis that such positive outcomes are the results of the β-blockers’ (BB) ability to downregulate the hyperadrenergic activity which is generated by the trauma and surgery.12 13 The adrenergic hyperactivity state imposes great strain on the cardiovascular system, metabolic and hormonal pathways, as well as immunomodulation. This ultimately leads to a decreased recovery potential and an increased risk of adverse postoperative outcomes such as sepsis, cardiovascular adverse events, multiorgan failure, and ultimately death.14 15

    There are no previous studies investigating the association between β-adrenergic blockade and mortality in patients undergoing orthopedic surgery for hip fractures. The aim of the current retrospective cohort study is to investigate if such a relationship exists with the hypothesis that BB therapy will reduce the risk of short-term postoperative mortality.

    Methods

    The study population was obtained from the Rikshöft registry.16 The Rikshöft registry is a prospectively collected national registry for hip fractures and was set up in 1988. All consecutive patients aged 40 years and above who underwent primary surgery for an isolated hip fracture between January 1, 2013 and December 31, 2017 in Örebro County were included and retrospectively analyzed. Örebro County has three hospitals: Örebro University Hospital and two university-affiliated regional hospitals. Patients with a pathological fracture were excluded. Patients who suffered a hip fracture on both the right and the left hip during the study period were included as two separate cases unless they died within the 90-day postoperative follow-up period. In the event of a patient having a second surgery within the 90-day follow-up period they were only counted as one case, that is, the first hip fracture surgery. Variables obtained from the Rikshöft registry were age, sex, type of fracture, date of hospital admission, American Society of Anesthesiologists (ASA) classification, surgical method and date of hospital discharge. In addition to registry data, patients’ electronic medical records were reviewed to obtain comorbidity data, time of death and information regarding BB prescriptions and administration. Patients were divided into BB positive (+) and BB negative (−) groups based on whether or not they had ongoing BB therapy at the time of surgery. Comorbidity data were used to calculate a Charlson Comorbidity Index (CCI) for each patient.17 The CCI includes the diagnosis of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular events, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, chronic kidney disease, cancer, leukemia, lymphoma and AIDS. The review of patients’ electronic medical records also allowed the completion of missing data from the national Rikshöft registry.

    Statistical analysis

    Patient demographics and clinical characteristics were compared between the groups using the χ2 test for categorical variables and the Student’s t-test or Mann-Whitney U test for continuous variables as appropriate. The primary outcome of interest was 90-day mortality after hip fracture surgery. The crude incidence rates of 30-day and 90-day mortality in the two groups were compared using the χ2 test and hospital length of stay was compared using the Mann-Whitney U test. Poisson regression models with robust standard errors of variance were deployed to evaluate the effect of BB therapy on 30-day and 90-day postoperative mortality. The time from surgery to death or to the end of the 90-day follow-up period was used as an offset in the Poisson regression models. The regression models were adjusted for age, sex, ASA classification, CCI, type of fracture, and surgical intervention. Adjustment for type of fracture and surgical intervention was made to control for the stress reaction caused by the injury itself as well as the surgical trauma. Results are reported as incidence rate ratio (IRR) with 95% CI. Statistically significant results were defined as a p value <0.05 throughout all statistical analyses. No power analysis for sample size was performed. All statistical analyses were preformed using Statistical Package for Social Science (SPSS Windows) V.25 (IBM) and Stata V.15 (StataCorp, College Station, Texas).

    Results

    A total of 2443 patients met the inclusion criteria of whom 900 (36.8%) had ongoing β- blocker therapy at the time of surgery. Six patients under 40 years of age were excluded per the study inclusion criteria. No patients were excluded due to a second operation during the 90-day postoperative follow-up period. No patients suffered simultaneous bilateral hip fractures. This level of drug exposure was in line with the proportion BB users in the general population in Örebro County, which was 36% for the same age group and time period as that of the current study cohort.18 The Rikshöft registry had a coverage of 93% for hip fractures in Örebro County during the study period. All patients with BB therapy were continued on their normally prescribed BB agent throughout their hospital admissions.

    In the BB (+) group, 595 (66.0%) patients were female compared with 1049 (68.0%) patients in the control group (p=0.341). Patients in the BB (+) group were significantly older (83 (SD 8) years vs. 81 (SD 11) years, p<0.001), less fit for surgery based on their American Society of Anesthesiologists classification (64.6% vs. 43.2% with ASA ≥3, p<0.001) and had a higher rate of comorbidities (80% vs. 61% with CCI ≥5, p<0.001). There were no statistically significant differences in the type of hip fracture or choice of surgical technique between groups (table 1).

    View this table:
    Table 1

    Patient demographics and clinical characteristics in β-blocker unexposed (BB−) and β-blocker exposed (BB+) patients undergoing surgery for hip fracture

    Furthermore, the BB (+) group had a higher prevalence of patients with a history of myocardial infarction (27.7% vs. 8.5%, p<0.001), heart failure (32.8% vs. 8.5%, p<0.001) and peripheral vascular disease (11.6% vs. 4.9%, p<0.001) prior to surgery. The prevalence of cerebrovascular disease, chronic kidney disease and diabetes was also significantly higher in the BB (+) group. There were more patients with dementia in the BB (−) group compared with the BB (+) group (26.2% vs. 18.8%, p<0.001) (table 2).

    View this table:
    Table 2

    Preoperative comorbidities in β-blocker unexposed (BB−) and β-blocker exposed (BB+) patients undergoing surgery for hip fracture

    Crude mortality was higher for both 30-day (9.1% vs. 7.7%) and 90-day mortality (16.1% vs. 13.5%) in the BB (+) cohort. These differences were statistically non-significant (table 3).

    View this table:
    Table 3

    Outcomes in β-blocker unexposed (BB−) and β-blocker exposed (BB+) patients undergoing surgery for hip fracture

    Multiple regression analysis found increasing age, ASA classification, increasing comorbidity burden, and male sex to be associated with increased 90-day mortality risk (table 4). After adjustments for clinically relevant variables, the Poisson regression model demonstrated a statistically significant 18% risk reduction for 90-day mortality (adjusted IRR 0.82, 95% CI 0.68 to 0.98, p=0.03) (table 4). Regression analysis for 30-day mortality revealed a non-significant trend towards decreased mortality risk in BB (+) patients (adjusted IRR 0.79, 95% CI 0.60 to 1.03, p=0.07) (table 3).

    View this table:
    Table 4

    Incidence rate ratio (IRR) for 90-day mortality after surgery for hip fracture

    Discussion

    This is the first study investigating the association between β-adrenergic blockade and mortality after surgery for traumatic hip fractures. Our results show a significant risk reduction in 90-day mortality for patients who had ongoing BB therapy, after adjusting for relevant patient and clinical variables.

    Both traumatic injury and surgical trauma are responsible for several physiological responses that are characterized by the activation of the sympathetic nervous system and mediated through the release of catecholamines. Although a necessary physiological response, the trauma-induced hyperadrenergic state may have prolonged or unwanted end-organ effects which could affect clinical outcomes. The most pronounced end-organ effect of adrenergic hyperactivity is seen on the cardiovascular system and can lead to cardiac complications such as arrhythmias or myocardial infarction specially in patients with prior heart disease.19 Several studies show that adverse cardiovascular events are a common cause of death in patients undergoing surgery for hip fractures.2 20 21 In cardiac surgery, there is strong evidence (level 1a) for the protective effects of β-blockade with a decreased risk of postoperative complications and higher degree of survival.6 According to universal guidelines set by the American Heart Association/American College of Cardiology and European Society of Cardiology, BB therapy should not be discontinued before or after either cardiac or non-cardiac surgery.22 23

    Adrenergic hyperactivity also leads to an increase in the levels of growth hormone and antidiuretic hormone which affect the pancreatic release of glucagon and insulin with a net result of catabolic activity. This results in an increase in glucose levels and peripheral insulin resistance.13–15 The immune response is altered with a net increase in the production of proinflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor alpha (TNF-α). If prolonged, this can lead to multiple organ injury and subsequent organ failure. Unregulated, the inflammatory response can predispose to sepsis and overwhelming, hard-to-control inflammatory conditions.13 14 BB therapy has shown an association with reduced mortality in patients suffering from sepsis.24 A systematic review by Tan et al, including nine studies with a total of 56 414 patients, investigated the effect of β-blockade on sepsis. The results of this systematic review suggest that BB therapy, prior to developing full-blown sepsis, is associated with significantly reduced mortality.24 Both in vivo and in vitro studies have shown that β-blockade downregulates the degree of circulating proinflammatory factors IL-6 and TNF-α, which could explain the drug’s beneficial use in acting as an inflammatory balancing agent.12 13 25

    A hyperadrenergic reaction after hip fractures, as with other traumatic injuries, is expected and could have the same devastating effects on outcomes. β-blockade therapy has previously shown an association with reduced mortality in patients suffering from non-orthopedic traumatic injury. Traumatic brain injury (TBI) is well known for inducing a hyperadrenergic state and is strongly associated with extracranial complications. Most notably are those of cardiac and pulmonary nature which underlie a large extent of the high mortality seen in brain injury victims.26 27 Mohseni et al studied the effect of β-blockade on survival after isolated severe TBI and detected a significant decrease in mortality in patients who had an ongoing BB therapy prior to their TBI (adjusted OR=0.29, 95% CI 0.14 to 0.60, p=0.001).8 A recent published prospective randomized controlled trial by Khalili et al showed the same positive results in patients with isolated severe TBI who received early BB.9 Bukur et al also reported similar positive results in a study on critically ill trauma patients without severe head injuries.7

    In addition, similar adverse effects of adrenergic hyperactivity are seen in major non-cardiac surgery.15 BB therapy has also been shown to be protective and associated with better overall outcomes after major surgery.6 A study by Lindenauer et al, consisting of almost 800 000 patients undergoing intrathoracic, intraperitoneal and suprainguinal vascular procedures, showed reduced in-hospital mortality in patients on BB therapy.19 Ahl and colleagues conducted a study on patients undergoing emergency surgery for colon cancer and showed a significant increase in survival up to 1 year postoperatively in BB-treated patients (adjusted HR=0.40, 95% CI 0.26 to 0.62, p<0.001).10 The same positive results were obtained when looking at mortality after rectal cancer surgery.11

    Patients incurring hip fractures are known to be older and have a higher comorbidity burden. This predisposes them to worse outcomes.2 20 21 28 29 A recent study by Gundel et al, which used data from Denmark’s national register, included 113 957 patients with a hip fracture during a 15-year period. They found 9.6%, 16%, and 27% postoperative mortality rates after surgery at 30 days, 90 days and 1 year, respectively. Interestingly, the authors did not find any trend towards an increase or decrease in mortality during the 15-year study period despite national efforts to improve overall outcomes with the implementation of orthogeriatric collaborations and fast-track surgery during the last decade.2 5 Overall 30-day and 90-day mortality in our cohort were 8.2% and 14.5%, respectively. Previous studies have reported male sex, increasing age and increasing CCI to be significant risk factors for mortality after surgery for hip fractures.2 In the current study, male sex, increasing age, ASA classification, and comorbidities were also significant risk factors for 90-day mortality. After adjusting for clinically relevant risk factors, an 18% reduction in the incidence of 90-day postoperative mortality was detected in the current study (adjusted IRR 0.82, 95% CI 0.68 to 0.98, p=0.03). There was no significant protective effect seen in the immediate (30-day) postoperative period. One possible explanation for this discrepancy could be if there were a higher rate of do not resuscitate or limited advance directives in patients on BB therapy. This would not be surprising since the BB group was significantly older, had higher ASA classification scores, and had a higher comorbidity burden. This is, however, purely a possible hypothesis by the authors and cannot be supported by data due to the lack of patient information regarding resuscitative status in the event of cardiac arrest nor restriction of care.

    The strength of the current study is founded in the use of a prospectively collected database with access to in-hospital medical records. However, there are important limitations to the current study. The inclusion of patients is limited to one university hospital and two university-affiliated hospitals. This could affect the generalizability of the results. Although the Rikshöft registry is a prospectively collected database, the coverage was limited to 93% in the studied county. Although electronic medical records were reviewed for continuation of preadmission BB therapy, no attempt was made to collect data concerning changes in dosage or missing doses during the hospital stay. Further, type of anesthesia, postoperative complications, or organ failures requiring invasive support such as mechanical ventilation or dialysis, were not collected in the current database. Additionally, cause-specific mortality could not be recorded due to the fact that the majority of deaths occurred after discharge from the hospital.

    Conclusion

    The results of this observational study support a potential protective role of early β-blockade in patients undergoing surgery for hip fractures. This finding warrants further investigation.

    References

    1. ↵
      1. Kanis JA,
      2. Odén A,
      3. McCloskey EV,
      4. Johansson H,
      5. Wahl DA,
      6. Cooper C
      . A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012;23:2239–56.doi:10.1007/s00198-012-1964-3pmid:22419370
      OpenUrlCrossRefPubMed
    2. ↵
      1. Gundel O,
      2. Thygesen LC,
      3. Gogenur I,
      4. Ekeloef S
      . Postoperative mortality after a hip fracture over a 15-year period in Denmark: a national register study. Acta Orthop 2019:1–5.
    3. ↵
      1. Cenzer IS,
      2. Tang V,
      3. Boscardin WJ,
      4. Smith AK,
      5. Ritchie C,
      6. Wallhagen MI,
      7. Espaldon R,
      8. Covinsky KE
      . One-Year mortality after hip fracture: development and validation of a prognostic index. J Am Geriatr Soc 2016;64:1863–8.doi:10.1111/jgs.14237pmid:http://www.ncbi.nlm.nih.gov/pubmed/27295578
      OpenUrlPubMed
    4. ↵
      1. Polischuk MD,
      2. Kattar N,
      3. Rajesh A,
      4. Gergis T,
      5. King K,
      6. Sriselvakumar S,
      7. Shelfoon C,
      8. Lynch G,
      9. Campbell K,
      10. Cooke C
      . Emergency department femoral nerve blocks and 1-year mortality in fragility hip fractures. Geriatr Orthop Surg Rehabil 2019;10:215145931989389.doi:10.1177/2151459319893894pmid:http://www.ncbi.nlm.nih.gov/pubmed/31903295
      OpenUrlPubMed
    5. ↵
      1. Kates SL
      . Hip fracture programs: are they effective? Injury 2016;47 Suppl 1:S25–7.doi:10.1016/S0020-1383(16)30006-7pmid:http://www.ncbi.nlm.nih.gov/pubmed/26768285
      OpenUrlPubMed
    6. ↵
      1. Blessberger H,
      2. Kammler J,
      3. Domanovits H,
      4. Schlager O,
      5. Wildner B,
      6. Azar D,
      7. Schillinger M,
      8. Wiesbauer F,
      9. Steinwender C
      . Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2018;3:CD004476.doi:10.1002/14651858.CD004476.pub3pmid:http://www.ncbi.nlm.nih.gov/pubmed/29533470
      OpenUrlPubMed
    7. ↵
      1. Bukur M,
      2. Lustenberger T,
      3. Cotton B,
      4. Arbabi S,
      5. Talving P,
      6. Salim A,
      7. Ley EJ,
      8. Inaba K
      . Beta-Blocker exposure in the absence of significant head injuries is associated with reduced mortality in critically ill patients. Am J Surg 2012;204:697–703.doi:10.1016/j.amjsurg.2012.02.007pmid:http://www.ncbi.nlm.nih.gov/pubmed/22578406
      OpenUrlCrossRefPubMed
    8. ↵
      1. Mohseni S,
      2. Talving P,
      3. Thelin EP,
      4. Wallin G,
      5. Ljungqvist O,
      6. Riddez L
      . The effect of β-blockade on survival after isolated severe traumatic brain injury. World J Surg 2015;39:2076–83.doi:10.1007/s00268-015-3039-zpmid:http://www.ncbi.nlm.nih.gov/pubmed/25809062
      OpenUrlPubMed
    9. ↵
      1. Khalili H,
      2. Ahl R,
      3. Paydar S,
      4. Sjolin G,
      5. Cao Y,
      6. Abdolrahimzadeh Fard H,
      7. Niakan A,
      8. Hanna K,
      9. Joseph B,
      10. Mohseni S
      . Beta-Blocker therapy in severe traumatic brain injury: a prospective randomized controlled trial. World J Surg 2020;44:1844–53.doi:10.1007/s00268-020-05391-8pmid:http://www.ncbi.nlm.nih.gov/pubmed/32002583
      OpenUrlPubMed
    10. ↵
      1. Ahl R,
      2. Matthiessen P,
      3. Cao Y,
      4. Sjolin G,
      5. Ljungqvist O,
      6. Mohseni S
      . The relationship between severe complications, beta-blocker therapy and long-term survival following emergency surgery for colon cancer. World J Surg 2019;43:2527–35.doi:10.1007/s00268-019-05058-zpmid:http://www.ncbi.nlm.nih.gov/pubmed/31214833
      OpenUrlPubMed
    11. ↵
      1. Ahl R,
      2. Matthiessen P,
      3. Fang X,
      4. Cao Y,
      5. Sjolin G,
      6. Lindgren R,
      7. Ljungqvist O,
      8. Mohseni S
      . β-Blockade in rectal cancer surgery: a simple measure of improving outcomes. Ann Surg 2020;271:140–6.doi:10.1097/SLA.0000000000002970pmid:http://www.ncbi.nlm.nih.gov/pubmed/30048321
      OpenUrlPubMed
    12. ↵
      1. Friese RS,
      2. Barber R,
      3. McBride D,
      4. Bender J,
      5. Gentilello LM
      . Could beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma 2008;64:1061–8.doi:10.1097/TA.0b013e3181684cf0pmid:http://www.ncbi.nlm.nih.gov/pubmed/18404076
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      1. Loftus TJ,
      2. Efron PA,
      3. Moldawer LL,
      4. Mohr AM
      . β-Blockade use for traumatic injuries and immunomodulation: a review of proposed mechanisms and clinical evidence. Shock 2016;46:341–51.doi:10.1097/SHK.0000000000000636pmid:http://www.ncbi.nlm.nih.gov/pubmed/27172161
      OpenUrlPubMed
    14. ↵
      1. Moor D,
      2. Aggarwal G,
      3. Quiney N
      . Systemic response to surgery. Surgery 2017;35:220–3.doi:10.1016/j.mpsur.2017.01.013
      OpenUrl
    15. ↵
      1. Desborough JP
      . The stress response to trauma and surgery. Br J Anaesth 2000;85:109–17.doi:10.1093/bja/85.1.109pmid:http://www.ncbi.nlm.nih.gov/pubmed/10927999
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      1. Rikshoft
      . Swedish National Registry of hip fracture patient care. https://rikshoft.se/about-rikshoft/.
    17. ↵
      1. Charlson ME,
      2. Pompei P,
      3. Ales KL,
      4. MacKenzie CR
      . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.doi:10.1016/0021-9681(87)90171-8pmid:http://www.ncbi.nlm.nih.gov/pubmed/3558716
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      1. SNBHW
      . Swedish National Board of Health and Welfare, medical register. https://sdb.socialstyrelsen.se/if_lak/resultat.aspx (29 Jan 2020).
    19. ↵
      1. Lindenauer PK,
      2. Pekow P,
      3. Wang K,
      4. Mamidi DK,
      5. Gutierrez B,
      6. Benjamin EM
      . Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005;353:349–61.doi:10.1056/NEJMoa041895pmid:http://www.ncbi.nlm.nih.gov/pubmed/16049209
      OpenUrlCrossRefPubMedWeb of Science
    20. ↵
      1. Choi HG,
      2. Lee YB,
      3. Rhyu SH,
      4. Kwon BC,
      5. Lee JK
      . Mortality and cause of death postoperatively in patients with a hip fracture: a national cohort longitudinal follow-up study. Bone Joint J 2018;100-B:436–42.doi:10.1302/0301-620X.100B4.BJJ-2017-0993.R2pmid:http://www.ncbi.nlm.nih.gov/pubmed/29629585
      OpenUrlPubMed
    21. ↵
      1. Panula J,
      2. Pihlajamäki H,
      3. Mattila VM,
      4. Jaatinen P,
      5. Vahlberg T,
      6. Aarnio P,
      7. Kivelä S-L
      . Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. BMC Musculoskelet Disord 2011;12:105. doi:10.1186/1471-2474-12-105pmid:http://www.ncbi.nlm.nih.gov/pubmed/21599967
      OpenUrlCrossRefPubMed
    22. ↵
      1. Fleisher LA,
      2. Fleischmann KE,
      3. Auerbach AD,
      4. Barnason SA,
      5. Beckman JA,
      6. Bozkurt B,
      7. Davila-Roman VG,
      8. Gerhard-Herman MD,
      9. Holly TA,
      10. Kane GC, et al
      . 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: Executive summary: a report of the American College of Cardiology/American heart association Task force on practice guidelines. Circulation 2014;130:2215–45.doi:10.1161/CIR.0000000000000105pmid:http://www.ncbi.nlm.nih.gov/pubmed/25085962
      OpenUrlFREE Full Text
    23. ↵
      1. López-Sendón J,
      2. Swedberg K,
      3. McMurray J,
      4. Tamargo J,
      5. Maggioni AP,
      6. Dargie H,
      7. Tendera M,
      8. Waagstein F,
      9. Kjekshus J,
      10. Lechat P, et al
      . Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25:1341–62.doi:10.1016/j.ehj.2004.06.002pmid:http://www.ncbi.nlm.nih.gov/pubmed/15288162
      OpenUrlCrossRefPubMedWeb of Science
    24. ↵
      1. Tan K,
      2. Harazim M,
      3. Tang B,
      4. Mclean A,
      5. Nalos M
      . The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review. Crit Care 2019;23:298.doi:10.1186/s13054-019-2562-ypmid:http://www.ncbi.nlm.nih.gov/pubmed/31484576
      OpenUrlPubMed
    25. ↵
      1. Rough J,
      2. Engdahl R,
      3. Opperman K,
      4. Yerrum S,
      5. Monroy MA,
      6. Daly JM
      . Beta2 adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury. Surgery 2009;145:235–42.doi:10.1016/j.surg.2008.09.013pmid:http://www.ncbi.nlm.nih.gov/pubmed/19167980
      OpenUrlCrossRefPubMedWeb of Science
    26. ↵
      1. Kemp CD,
      2. Johnson JC,
      3. Riordan WP,
      4. Cotton BA
      . How we die: the impact of nonneurologic organ dysfunction after severe traumatic brain injury. Am Surg 2008;74:866–72.doi:10.1177/000313480807400921pmid:http://www.ncbi.nlm.nih.gov/pubmed/18807680
      OpenUrlPubMed
    27. ↵
      1. Zygun DA,
      2. Kortbeek JB,
      3. Fick GH,
      4. Laupland KB,
      5. Doig CJ
      . Non-neurologic organ dysfunction in severe traumatic brain injury. Crit Care Med 2005;33:654–60.doi:10.1097/01.CCM.0000155911.01844.54pmid:http://www.ncbi.nlm.nih.gov/pubmed/15753760
      OpenUrlCrossRefPubMedWeb of Science
    28. ↵
      1. Cher EWL,
      2. Allen JC,
      3. Howe TS,
      4. Koh JSB
      . Comorbidity as the dominant predictor of mortality after hip fracture surgeries. Osteoporos Int 2019;30:2477–83.doi:10.1007/s00198-019-05139-8pmid:http://www.ncbi.nlm.nih.gov/pubmed/31451838
      OpenUrlPubMed
    29. ↵
      1. Schnell S,
      2. Friedman SM,
      3. Mendelson DA,
      4. Bingham KW,
      5. Kates SL
      . The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil 2010;1:6–14.doi:10.1177/2151458510378105pmid:http://www.ncbi.nlm.nih.gov/pubmed/23569656
      OpenUrlCrossRefPubMed

    Footnotes

    • Presented at The abstract has been accepted for presentation in Orthopaedic Trauma Association (OTA) Annual Meeting in September 2020.

    • Contributors Study design: SM, AMI, TB, RA. Data collection: SM, AMI, AP, SH. Analysis and interpretation of data: SM, AMI, GS, YC, RA, TB, PW. Article draft: SM, AMI, RA, TB, PW. All authors have critically revised and accepted the submitted article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval Ethical approval was obtained from the Swedish Ethical Review Authority (reference 2019-02094). The principles of the Declaration of Helsinki and Strengthening the Reporting of Observational Studies in Epidemiology guidelines were adhered too.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available upon reasonable request. According to the granted IRB the data are only to be accessed by the research team. However, upon reasonable request, the authors will seek extension from the IRB for the editorial board to have access to the data.